Research tool page — not in the public editorial index
This company can still be explored inside Wall Street Score, but this URL remains noindex and is not eligible for Google-served ads until source-specific publisher curation is documented and the public research-quality checks pass.
Skye Bioscience, Inc.
The research record contains a warning or limitation that requires review before a complete Wall Street Score can be published. Available company and financial research remain accessible.
SKYE · Price history
Price at last available close
$1.37
−$0.24 (-14.91%) 1M
2026-10-30
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Skye Bioscience, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
How they make money
Skye Bioscience is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model is focused on the research and development of proprietary pharmaceutical candidates, specifically targeting G-protein coupled receptors to treat metabolic diseases like obesity, and it relies on raising capital to fund these operations.
Products & services
The company's lead drug candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody designed to target the cannabinoid receptor 1 (CB1) for the treatment of obesity and metabolic disorders.
Brands & revenue mix
Lead clinical-stage antibody drug candidate targeting CB1 receptors.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Patients with obesity and metabolic diseasesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company utilizes third-party service providers for clinical trial management, drug substance manufacturing, and other research-related services. Specific supplier names are not disclosed.Source
Strengths
- Proprietary pipeline focused on CB1 receptor modulationSource
Sources
Company-specific research
Questions worth answering for SKYE
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can SKYE fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is SKYE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for SKYE to reach sustainable profitability?
- •What future growth or profitability would be needed to justify SKYE's current valuation?
- •What does the current missing revenue history warning mean for the reliability or interpretation of SKYE's score?
Essential Investment Snapshot
Market Cap
$5.9M
P/E Ratio
-0.2
EPS
$-10.16
52-Week High
$13.28
52-Week Low
$1.50
Beta
2.86
Analyst Target
$15.00
Shares Outstanding
5.0M
Total Debt
$36K
Dividend
No current dividend
Liquidation Value / Share
$-0.10
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on SKYE.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary pipeline focused on CB1 receptor modulation.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and dependence on future capital raises.
- −Clinical trial failure or regulatory delays.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$1.33
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $173K | $723K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$173K | -$723K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $32.5M | $42.4M | $18.7M | $5.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $15.9M | $15.8M | $17.7M | $7.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $51.7M | $57.4M | $30.2M | $34.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$49.8M | -$55.2M | -$25.3M | -$36.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$51.9M | -$58.2M | -$30.2M | -$34.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $5K | $0.00 | $968K | $906K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$50.5M | -$55.9M | -$26.6M | -$37.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $3K | $5K | $10K | $4K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$50.5M | -$55.9M | -$26.6M | -$37.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-10.16 | $-11.28 | $-5.84 | $-42.96 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 4.96M | 4.96M | 4.56M | 876K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 4.96M | 4.96M | 4.56M | 876K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$2.16
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-90.3%
Cash Change
-66.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 38.6%. Cash declined 66.2%. Total debt declined 90.3%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Rumor Mill · SKYE
Corporate developments & opportunities
No reviewed developments match this filter.
The reliability percentage measures the strength of the supporting evidence—not the probability that the event will occur or that the stock will rise. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial